🇺🇸 FDA
Patent

US 12233092

MSC-NTF specific exosomes and use thereof

granted A61KA61K35/28A61K38/00

Quick answer

US patent 12233092 (MSC-NTF specific exosomes and use thereof) held by BRAINSTORM CELL THERAPEUTICS LTD. expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BRAINSTORM CELL THERAPEUTICS LTD.
Grant date
Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K35/28, A61K38/00, A61K38/18, A61K38/1866